The company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics branded formulations India business amounting to Rs 350 crore and a gain of Rs 456 crore from Biocons stake dilution in Bicara Therapeutics.
Biocon Share Price Falls 9% After Q3 Profit Dips 18% YoY To Rs 186 Crore moneycontrol.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from moneycontrol.com Daily Mail and Mail on Sunday newspapers.